Ed Bio and Merck have reached an accompanying diagnostic collaboration with Ai Huijian Upgrade to launch registration on a daily date.

In 2016, Ed Bio and Merck launched the global colorectal cancer RAS testing program, the cooperation between the two sides has recently expanded into new areas.
Ed Bio announced on the 10th that it had recently signed a cooperation agreement with Merck.
Ed Bio's PCR technology platform-based "Lung Cancer Multigene Joint Detection Product" (i.e., Ai Huijian® Upgrade) will be used in the accompanying diagnostic registration of Merck MET inhibitor Tepotinib in Japan.
Tepotinib is the world's first approved oral MET inhibitor for patients with advanced NSCLC patients carrying a mutation in the MET gene, which was approved by Japan's Ministry of Health, Labour and Health in March this year for the treatment of non-small cell lung cancer patients with the MET exon 14 jump mutation.
recent years, lung cancer has become the largest cancer in China.
according to the national cancer statistics released by the National Cancer Center in January 2019, the number of lung cancer cases in China is 784,000, and the incidence and mortality rate of lung cancer is already among the highest in malignant tumors.
the emergence of targeted drugs is a boon to patients, but targeted drugs are not suitable for all patients, so accurate diagnosis is the basis for ensuring the success of individual cancer diagnosis and treatment.
In the current treatment of lung cancer, EGFR, ALK, ROS1 and so on are common targets of lung cancer and have corresponding target drugs, while MET, HER2, RET, etc. are rare targets, the research and development of related drugs and clinical research is still under way.
the Ed Bio-Research Ai Huijian ® is an accompanying diagnostic product for the rare target MET.
2018, Ai Huijian's ® approved for listing in China.
According to previous media reports, the kit is based on ADx-ARMS® core technology platform products, can detect lung cancer EGFR, ALK, ROS1, KRAS, BRAF, HER-2, RET, MET, NRAS, PIK3CA and other core driver genes, and gene mutation and gene fusion detection into the same product, to ensure that the results can be reported on the same day, the rapid detection of different types of genetic variation.
at present, Ai Huijian ® has started registration in Japan for approval.
was founded in 2008, Ed Bio is China's first cancer precision medical molecular diagnostic reagent research and development enterprises, with fully independent intellectual property rights of ADx-ARMS ®, Super-ARMS® two technology platforms.
2017, when Ed Bio went public, its vice president, Zhu Guanshan, said that Ed Bio was developing two product lines of accompanying diagnostic reagents based on PCR technology and second-generation sequencing technology.
notably, this is not the first time Ed Bio has worked with Merck.
2016, Ed Bio signed a partnership agreement with Merck to launch the Merck-Ed Bio "Precision Detection, Precision Treatment" colorectal cancer RAS testing program.
the project is dedicated to the development and promotion of new RAS liquid biopsies in colorectal cancer detection worldwide, as well as the promotion of RAS testing in Chinese mainland tissues.
in addition to working with Merck, Ed Bio has also partnered with a number of multinational pharmaceutical companies in recent years on targeted drug-accompanied diagnostics.
In June this year, Ed Bio and AstraZenewan jointly cooperate in the integrated diagnosis and treatment of lung cancer products agency business, with the advantages of their respective resources to popularize lung cancer detection and diagnosis, improve the prevalence and accuracy of detection and diagnosis, and promote the development of individual diagnosis and treatment of lung cancer.
And in terms of products, based on the PCR technology platform independently developed "lung cancer multi-gene joint detection products" (i.e., Ai Huijian® Upgrade), but also Lilly, Amgen and other companies targeted drugs accompanied by diagnostic products.
in the field of NGS platform, Ed Bio's self-developed ® is a diagnostic product line of tumor products such as Johnson and Johnson, Lilly, etc.
.